Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, New York, NY 11030, USA.
Trends Immunol. 2011 Aug;32(8):388-94. doi: 10.1016/j.it.2011.06.004. Epub 2011 Jul 13.
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells, and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF inhibitor, belimumab, is the first new drug in 50 years to be approved for the treatment of SLE. However, the mechanism of action of this drug is not entirely clear. In this review we will focus on the role of the BAFF-APRIL signaling pathway in the selection of autoreactive B cells, and discuss whether altered selection is the mechanism for the therapeutic efficacy of BAFF inhibition in SLE.
B 细胞激活因子（BAFF）是过渡性和成熟 B 细胞的关键生存因子，是治疗系统性红斑狼疮（SLE）的有前途的治疗靶点。BAFF 抑制剂贝利尤单抗是 50 年来批准用于治疗 SLE 的第一种新药。然而，该药物的作用机制尚不完全清楚。在这篇综述中，我们将重点讨论 BAFF-APRIL 信号通路在自身反应性 B 细胞选择中的作用，并讨论改变选择是否是 BAFF 抑制治疗 SLE 疗效的机制。
